Скачать с ютуб Cancer Immunotherapy Clinical Trials with Dr. Kunle Odunsi в хорошем качестве

Cancer Immunotherapy Clinical Trials with Dr. Kunle Odunsi

CRI Scientific Advisory Council Associate Director Kunle Odunsi, M.D., Ph.D., of the University of Chicago Medicine Comprehensive Cancer Center discusses what clinical trials are and what patients need to know when considering a trial. #CRIsummit #immunotherapy https://summit.cancerresearch.org/ 00:00- Tamron Hall introduces Dr. Kunle Odunsi 01:16- Dr. Odunsi discusses clinical trials for immunotherapy 18:52- Dr. Odunsi takes questions from the audience Clinical trials are essential to bringing promising new therapies to patients, often for the first time or in new combinations with other treatments. What is a clinical trial? What are common misconceptions about clinical trials? How can you access and enroll in a cancer immunotherapy clinical trial? How has the COVID-19 pandemic changed patient participation in cancer clinical trials? https://www.cancerresearch.org/en-us/... Questions from the audience for Dr. Odunsi: What is next-generation sequencing and how does it relate to immunotherapy? As a cancer survivor, how can I get involved in improving clinical trial design for others? How do institutions approach clinical trials for cancers that are rare enough to not have very many people with the cancer at the same time? I have had tumor genome testing. Will this hurt my chance of getting into an immunotherapy clinical trial? At what point in my treatment should I start looking for a clinical trial? How long do clinical trials need to go on before a drug can be approved by the FDA? How do you think we can improve the accessibility of clinical trials for patients who live far away from cancer research centers? I currently have no evidence of disease. Can I still enroll in a clinical trial for immunotherapy? I had to leave an immunotherapy clinical trial because of a side effect. Can I still get access to the drug off the trial? Does a physician always have to make a referral for you to join a clinical trial? Dr. Kunle Odunsi is the director of the University of Chicago Medicine Comprehensive Cancer Center and dean for oncology at the University of Chicago’s Biological Services Division. His research efforts focus upon the mechanisms of immune recognition in ovarian cancer and the pre-clinical and clinical development of tumor antigen-targeted therapies, which are currently being studied in several cancer immunotherapy clinical trials. His contributions to science include the first demonstration of the importance of intraepithelial CD8+ T cell infiltration on favorable outcomes in ovarian cancer patients and the discovery of unique T cell receptors from rare subsets of CD8+ and CD4+ antigen-specific T cells. https://www.cancerresearch.org/en-us/... The 2021 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. It was offered free of charge, connecting cancer patients and caregivers with scientific and medical experts. This year’s Summit highlighted the growing implications of immunotherapy for more than 10 cancer types, provided education on the basics of immunotherapy and how clinical trials work, and addressed cancer care disparities. https://www.cancerresearch.org/en-us/... Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.